Lung cancer and immunotherapy: a real-life experience from second line and beyond

Autor:	Marwan Ghosn, Joseph Kattan, Elie El Rassy, Hazem I. Assi, Maya Al Ghor, F. Nasr, Nizar Ahmadieh, Nour Abdul Halim, Fady Gh Haddad, Fady El Karak, Fadi Farhat, Roland Eid, Theresia Choullamy, Arafat Tfayli
Rok vydání:	2019
Předmět:	0301 basic medicine Oncology Male Cancer Research medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Immune checkpoint inhibitors B7-H1 Antigen 03 medical and health sciences 0302 clinical medicine Second line Antineoplastic Agents Immunological T-Lymphocyte Subsets Partial response Internal medicine medicine Overall survival Biomarkers Tumor In real life Humans Lung cancer Aged Chemotherapy business.industry General Medicine Immunotherapy Middle Aged medicine.disease Prognosis 030104 developmental biology Treatment Outcome 030220 oncology & carcinogenesis Retreatment Female business
Zdroj:	Future oncology (London, England). 15(26)
ISSN:	1744-8301
Popis:	Aim: This study assessed the efficacy of anti-PD-1/PD-L1 agents in real life when used in second line or beyond. Materials & methods: Patients with advanced non-small-cell lung cancer progressing after standard chemotherapy and receiving immunotherapy in the second line or beyond were included. Results: One hundred and ten patients were included with PD-L1 expression above 50%, between 1–49 and
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01233390809feec43e036aa63eaefce5 https://pubmed.ncbi.nlm.nih.gov/31424958 Zobrazit plný text záznamu